Article Text

Download PDFPDF
Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Sources of funding: Pfizer; AstraZeneca; Daiichi Sankyo; Roche; Takeda; Sanofi-Aventis; Eli Lilly.